The incidence and significance of platelet activation in myocardial ischemia was evaluated by serial measurement of plasma thromboxane B2 (TXB2) and /3 thromboglobulin (,3TG) in plasma and urine in 98 patients admitted to a coronary care unit with chest pain. All measurements were normal in the 26 patients with noncardiac chest pain. Mean plasma TXB2 and J3TG concentration, but not urine /3TG, were elevated in the 25 patients with myocardial infarction and the 47 patients with angina. The /3TG levels remained normal in 61 % of the patients with angina or infarction. The TXB2 levels were significantly higher in patients with recurrent episodes of angina at rest than in those without ischemic episodes after admission. There was a weak correlation between plasma TXB2 and plasma ,BTG (r = 0.20, p < 0.01) and between plasma and urine I3TG (r = 0.31, p < 0.01). Results indicate that platelets are frequently activated with myocardial ischemia or infarction. However, the measurement of /3TG and TXB2 is of limited value in detecting or differentiating myocardial ischemia from infarction and therefore lacks clinical value in the management of patients with ischemic heart disease.
PLATELETS play an important role in the thrombotic and microembolic complications of coronary atherosclerosis. ' However, the role of platelets in myocardial ischemic events is uncertain. Numerous tests of platelet reactivity have been evaluated in patients with coronary artery disease (CAD) not only to establish the role of platelets in the pathogenesis and progress of the condition, but also to determine the effect of various therapeutic regimens directed at inhibition of platelet activation. However, most platelet tests provide only crude and indirect estimates of platelet activation in vivo and yield inconsistent results in CAD patients. Recently, highly specific, sensitive and reproducible radioimmunoassays of platelet release and prostaglandin synthesis were developed, including assays of 13 thromboglobulin (,3TG), platelet factor 4 (PF4) and thromboxane B, (TXB,).2 Both ,3TG and PF4 are platelet-specific proteins liberated from platelets into plasma during the release reaction and partially excret-ed through the kidneys. Increased levels of these proteins in plasma and urine may reflect in vivo platelet activation.' Thromboxane A, (TXA2), an end product of prostaglandin synthesis from arachidonic acid by platelets and other cells including leukocytes, is a potent proaggregating and vasoconstrictor agent.5 TXA, is rapidly and spontaneously degraded into the stable substance thromboxane B, (TXB,), which has no effect on platelet aggregation and can be measured by radioimmunoassay in plasma.6 Both TXB, and the plateletspecific proteins have been studied in patients with CAD.7-20 The results of these studies have been variable. This study was carried out to clarify the relationship of platelet release and thromboxane synthesis in reversible myocardial ischemia and myocardial necrosis by serial measurements of I3TG in plasma and urine and plasma TXB, in a group of well-defined patients admitted to the coronary care unit with chest pain suggestive of myocardial ischemia.
Patients and Methods
Ninety-eight patients who presented with chest pain and were admitted to the coronary care unit with suspected ischemic heart disease were studied. All Patients known to have taken antiplatelet drugs were excluded, and no patient received antiplatelet drugs in hospital. Some patients may have taken a random dose of aspirin within several days before their hospitalization. The attending physician prescribed all drug treatment and did not alter their regimen because of the study. All patients were routinely treated with lowdose heparin, 5000 units every 8 hours. Of the patients with angina, 88% were treated with long-acting nitrates and 50% with propranolol.
The first blood sample in more than one-half of cases was obtained at the time of admission and while the patient still had chest pain. The next sample was collected within 12 hours of admission (day 1). Additional samples were taken in the morning on the second and third days of admission; from the patients with a proved MI, an additional sample was taken on day 7.
No samples were collected in relation to cardiac catheterization, stress testing or surgery. In patients with an i.v. catheter, blood samples were collected from the other arm.
Urine samples were collected after initial voiding, from 0800-1200 hours on the first, second, and third days of admission, during which time the daily plasma sample was drawn.
The technique of collecting samples prevented in vitro activation of the prostaglandin pathway and release of /3TG. Blood was collected with minimal stasis using 21-gauge needles into 10-ml vacuum tubes that contained 1 ml of anticoagulant mixture (0.5 ml disodium EDTA, 660 ng/ml; 0.2 ml theophylline, 8.3 mg/ ml; 0.2 ml indomethacin, 180 mg/ml; 0.1 ml 2-chloradenosine, 0.4 mg/ml), which were kept chilled on ice.22 Platelet-poor plasma (PPP) was prepared by centrifugation at 2000 g for 60 minutes at 4°C; the middle third of the platelet-free plasma (PFP) was transferred to two plastic tubes and frozen at -70°C for batch processing of ,BTG and TXB2 by radioimmunoassay.
Urine was collected for /3TG assay without preservative and aliquots of urine were centrifuged at 2000 g for 10 minutes within 1 hour of collection and the supernatant was stored at -70°C.
Plasma ,3TG concentrations were determined by radioimmunoassay.23 The mean plasma,fTG concentration in 111 healthy volunteers was 25 ng/ml (geometric For the radioimmunoassay of /3TG in urine, standards or urine aliquots (100 ,tl) were preincubated for 24 hours with 100 pI of,TG antibody at a concentration that bound 30-40% of tracer. Tracer (100 pil) was then added and incubated for a further 24 hours. Bound ligand was separated from unbound ligand with second antibody and polyethylene glycol. The tubes were then centrifuged and the supernatant aspirated off. The pellet was counted in an automatic gamma counter (Beckman 7000). The sensitivity of the assay was 0.04 ng/ ml. The mean urine /3TG in 97 healthy volunteers was 0.09 ng/ml (geometric mean) (95% probability range 0.01-0.56 ng/ml), or 0.09; 0.0 1-0.60 ng ,3TG/ng creatinine, with excretion being constant throughout the day in healthy subjects.
TXB, levels were measured in plasma samples according to the method of Sors et al. 6 To 100 ,l of histamine-iodinated tracer in gelatinphosphate buffer (approximately 20,000 counts/min) were added 100 gl of standard or unknown and 100 ,ul of a dilution of the antibody which resulted in approximately 40% binding in the absence of standard after 24 hours' incubation at 4°C. Bound ligand was separated from the unbound ligand as described for the urine ,JTG assay. The sensitivity of the assay was 10 pg/ml, and the mean concentration in 30 healthy volunteers was 173 pg/ml (geometric mean) (95% probability range 74-269 pg/ml).
Statistical Analysis
Because of the non-normal distribution of the data, all results were transformed to the natural log before statistical analysis. The unpaired t test was used to determine the significance of differences between results in patients in the various diagnostic groups. Results are expressed as geometric mean with the 95% probability range. Because J3TG levels may be affected by conditions other than coronary ischemia or Ml, the data were also analyzed according to the presence or absence of several clinical measurements, including diabetes, congestive heart failure and smoking.
Results
Of the 98 patients admitted with chest pain, 25 had an acute MI, 47 difference between these diagnostic groups was observed. The mean age was significantly lower in the patients with nonischemic chest pain. In addition, they had a lower incidence of diabetes and hypertension.
Plasma ,3TG values are shown in figure 1 . The mean plasma ,BTG concentration in patients with noncardiac chest pain was not significantly different from normal and no elevated levels were recorded. In patients with acute MI, mean plasma J3TG was significantly elevated on admission and on the first, second and third hospital days compared with the patients with noncardiac pain. Levels tended to be higher at presentation and then fell progressively, and by day 3 were significantly lower (p < 0.05). The mean plasma,3TG concentration was higher in patients with angina than in control patients, but there was no difference between the patients with angina and MI ( chest pain and ,BTG concentration, samples from patients with unstable angina, collected during or within 4 hours of an attack of angina, were compared with those collected in pain-free periods. Mean plasma ,3TG in the samples collected in relation to chest pain was 38 ng/ml (range 10-155 ng/ml) (elevated in 27%) and in the remaining samples 31 ng/ml (range 13-71 ng/ml) (elevated in 11%), suggesting a relationship, but the difference was not statistically significant (p = 0.12).
Of the patients with CAD, 61% had normal plasma ,3TG concentrations throughout the study. Urine ,JTG data are shown in figure 2 . Mean urine ,3TG values in patients with acute MI or angina were not significantly different from values in the noncardiac patients and were frequently within the normal range (table 3). In the angina group, urine ,3TG levels were frequently abnormal on day 1, but rarely on days 2 or 3. Urine ,3TG levels in patients with stable and unstable angina were not significantly different. There was only a weak correlation between plasma and urine ,3TG in this group of patients (r = 0. 31, p < 0.01, n = 162). Plasma TXB2 results are shown in figure 3 . Patients with acute MI and angina had significantly higher noncardiac; MI = myocardial infarction; mean TXB, concentrations than the nonischemic controls. Levels in the angina group were higher than in the group with MI. The difference was statistically significant only at presentation and not on days 1-3. In the angina group, mean plasma TXB, was higher at presentation compared to the other 3 days of observation (NS) (table 4). Plasma TXB2 levels were significantly higher in patients with unstable angina than in patients with no further ischemic chest pain during admission (table 5). In the patients with unstable angina, samples collected within 4 hours of an attack of ischemic chest pain were higher (mean 400 pg/ml, range 89-1786 pg/ml) than in samples not related to clinically evident ischemia (mean 346 pg/ml, range 122-955 pg/ml) (NS). For the individual patient, the clinical value of the TXB, assay seemed limited, although a patient with unstable angina and elevated plasma /3TG levels who had an MI while in the hospital also had an increased plasma TXB, concentration before the infarct. There was a small but significant correlation between TXB, and /3TG plasma concentration (r = 0.31, p < 0.01, n = 325). There was no significant correlation (r = 0.009) between these two measures of platelet activation.
Several other factors influenced /3TG or TXB, levels. Seven of the patients with an acute MI had evidence of congestive heart failure, and their mean J3TG was significantly greater than that of MI patients without heart failure (table 6) . Urine ,/TG levels were also higher (NS). Of the three patients with urine /3TG values greater than 1 ng/ml, two had congestive heart failure. There was no difference in TXB2 levels between the two groups.
In the patients with major cardiac dysrhythmias, such as ventricular tachycardia or fibrillation or supraventricular tachycardia, no changes in either ,3TG or TXB2 were noted during the first 3 days of hospitalization. Two patients in the control group had diabetes, but their /3TG and TXB2 levels were not different from those in the other noncardiac patients. Thirteen patients with symptomatic CAD had diabetes, and their mean plasma /3TG concentration was significantly higher than that of CAD patients without diabetes (table 7) . The incidence of heart failure was also higher in the diabetes group, but even when these patients were excluded from the analysis, the difference persisted. There was no difference in TXB2 or urine /3TG between the diabetic and nondiabetic patients.
In the noncardiac group, smokers had normal ,3TG and TXB2 concentrations. However, CAD patients who smoked had significantly higher plasma ,ITG values than their nonsmoking counterparts (table 8) . TXB2 and urine /3TG values were not different in smokers.
Five additional patients with angina were studied who were treated with sulfinpyrazone before and during hospitalization. Their mean TXB2 (137 pg/ml; 56-325 pg/ml) was significantly (p < 0.005) lower compared with the angina patients not treated with sulfinpyrazone (288 pg/ml; 70-1181 pg/ml). Three of these patients had recurrent in-hospital ischemic episodes without change in TXB2 levels. The mean /3TG concentration in these patients (29 ng/ml; 8-125 ng/ml) was similar to that in the total angina group.
Discussion Stimulation of platelets, as measured both by release of specific proteins and activation of prostaglandin pathways, may occur in association with both revers- al. 16 Sobel et al. ' reported ,3TG values done during asymptomatic periods in a selected group of patients with unstable angina were normal but were elevated for several hours after an ischemic episode. We noted a similar trend in the present study. Elevated TXB2 levels were seen in patients with acute MI and angina, particularly in patients with recurrent episodes of angina during observation. Chierchia et al. 28 and Robertson et al. 29 reported that inhibition of cyclooxygenase with aspirin or indomethacin decreased TXB2 levels but did not affect frequency of ischemic episodes in patients with unstable angina. In the present study, similar results were observed in the five patients treated with sulfinpyrazone, all of whom had normal TXB2 levels despite episodes of ischemic chest pain. These data strongly suggest that TXA, synthesis is the result rather than the cause of myocardial ischemia in such patients, which is consistent with the conclusions of Hirsh et al.30
The stimulus to platelet release or prostaglandin synthesis during myocardial ischemia is uncertain, but various mechanisms may be involved, including the effects of thrombin synthesis or of catecholamines released into the circulation by such stimuli as pain or ischemia.
For the individual patient, there was no good correlation between plasma ,BTG and TXB, levels and clinical course, as indicated by recurrence of ischemic episodes or the progression to MI. A small but significant correlation between plasma ,3TG and TXB, levels was demonstrated, suggesting that platelet release and thromboxane synthesis are related phenomena of platelet activation in symptomatic CAD. The correlation coefficient of 0.31 is significantly less than that reported by Cella et al. ,^3 0.62, in patients after cardiac valve replacement. This is likely related to a difference in patient population. Our patients were not in a stable renovascular condition, which would influence the ,3TG and not the TXB, results.
The elevated /3TG levels in patients with congestive heart failure may relate to changes in renal function; the finding that TXB2 levels were unaffected supports this possibility.
Raised plasma /3TG levels were demonstrated in patients with diabetes,323 but plasma TXB, levels did not change, in agreement with a report by Davis et al. 34 However, arachidonic acid-induced synthesis of thromboxane by platelets in vitro is increased in patients with diabetes, especially those with vascular complications.
The J3TG levels were higher in coronary patients who smoked. This could not be explained by differences in age or incidence of diabetes and congestive heart failure in the groups of smokers. The TXB, levels were slightly elevated in patients with angina or acute MI, but significantly elevated levels may be seen in patients with recurrent episodes of angina at rest. Mean ,3TG levels were increased in patients with acute myocardial ischemia, although concentrations are frequently in the normal range. Urine I3TG levels are not increased in symptomatic CAD, and this further sug-gests platelet release occurs only intermittently and on a limited scale in patients with MI or angina. For clinical use, the assay of levels of plasma and urinary ,3TG and plasma TXB2 appears to have no value in the management of patients with ischemic heart disease.
